secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2026-04-01T23:59:59+00:00
Accession:  0001193125-26-137930
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics updates corporate presentation; highlights 212Pb pipeline with Phase 1/2a data in 2026
--------------------------------------------------------------------------------

- Phase 1/2a data for VMT-α-NET in neuroendocrine tumors shows durable disease control and best-in-class safety profile.
- VMT01 (212Pb-MC1R) for melanoma shows preliminary anti-tumor activity and tolerability; combination with checkpoint inhibitors planned.
- PSV359 targeting FAP-α for solid tumors demonstrates improved tumor retention; Phase 1/2a trial ongoing.
- Phase 1/2 data expected across all three clinical programs in 2026.
- Proprietary Pb-based chelator and Lead-212 isotope platform designed to optimize therapeutic index.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000119312526137930/0001193125-26-137930-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000119312526137930/catx-20260401.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-137930

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer